S
Scott M. Lippman
Researcher at University of California, San Diego
Publications - 676
Citations - 66362
Scott M. Lippman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 109, co-authored 651 publications receiving 60987 citations. Previous affiliations of Scott M. Lippman include Cleveland Clinic & Columbia University.
Papers
More filters
Journal ArticleDOI
Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson cancer center experience
Mihran Shirinian,Randal S. Weber,Scott M. Lippman,Isaiah W. Dimery,Charles L. Earley,Adam S. Garden,Jacqueline Michaelson,William H. Morrison,Alan M. Kramer,Robert M. Byers,Lester J. Peters,Waun Ki Hong,Helmuth Goepfert +12 more
TL;DR: The data suggest that laryngeal preservation was feasible in all three primary‐site subgroups and complete plus partial response rates to both cisplatin‐based induction regimens were comparable.
Journal Article
Second international cancer chemoprevention conference.
Journal ArticleDOI
Phase I Study of Intermittent Oral Dosing of the Insulin-Like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Robin L. Jones,Edward S. Kim,Pilar Nava-Parada,Salma Alam,Faye M. Johnson,A. W. Stephens,Ronit Simantov,Srinivasu Poondru,Richard Gedrich,Scott M. Lippman,Stan B. Kaye,Craig P. Carden +11 more
TL;DR: The maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary activity of OSI-906, a potent, oral, dual inhibitor of IGF1R and IR, in patients with advanced solid tumors is determined.
Journal ArticleDOI
Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention.
Xiao Chun Xu,Jin S. Lee,J. Jack Lee,Rodolfo C. Morice,Xiaoming Liu,Scott M. Lippman,Waun Ki Hong,Reuben Lotan +7 more
TL;DR: Results indicate that RARbeta is an independent marker of response to 13-cis-RA and may serve as an intermediate biomarker in chemoprevention trials of upper aerodigestive tract cancers.
Journal ArticleDOI
Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer
Yan Wang,Jian Gu,Jack A. Roth,Michelle A.T. Hildebrandt,Scott M. Lippman,Yuanqing Ye,John D. Minna,Xifeng Wu +7 more
TL;DR: The results suggest that serum miRNAs could serve as predictors of survival for advanced NSCLC.